Company registration number 03163208 (England and Wales)
HEALTHPOINT LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
HEALTHPOINT LIMITED
COMPANY INFORMATION
Directors
Mrs A Parkinson
Mr W Poppelaars
Mr W Meijerink
Company number
03163208
Registered office
Unit 11 Darwin Court
Blackpool Technology Park
Blackpool
FY2 0JN
Auditor
MHA
Richard House
9 Winckley Square
Preston
PR1 3HP
HEALTHPOINT LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3
Directors' responsibilities statement
4
Independent auditor's report
5 - 7
Group statement of comprehensive income
8
Group balance sheet
9
Company balance sheet
10
Group statement of changes in equity
11
Company statement of changes in equity
12
Group statement of cash flows
13
Notes to the financial statements
14 - 31
HEALTHPOINT LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -

The directors present the strategic report for the year ended 31 December 2024 for Healthpoint Limited and its subsidiaries (the "Healthpoint Group").

Review of the Healthpoint Group

Turnover amounted to £21.0m for the year ended 31 December 2024, compared with £21.7m for the year ended 31 December 2023.

 

Profit for the period after taxation amounted to £1.609m compared with £1.573m for the previous period.

 

Financial position

At the Balance Sheet date, shareholders’ funds showed a decrease of 48.8% compared with the previous period due to dividends paid in the restructure and the strike-off of HP14 and HP16.

 

Pressure on the cost of goods for resale remains, with excessive container prices, supply chain constraints brought on by the Ukraine war and the continued weakness of £Sterling against the US$ and Euro all contributing to a challenging environment.

 

In view of this the Directors consider the state of the Healthpoint Group's affairs to be satisfactory given the current economic climate.

Principal risks and uncertainties

We have set out below a number of risk factors that we believe could cause the Healthpoint Group's actual figures to differ materially from expected results. However, other factors could adversely affect the results and so the factors set out below should not be considered to be a complete set of all potential risks and certainties.

 

Business conditions and the general economy

The profitability of the Healthpoint Group could be adversely affected by a worsening of general economic conditions in the United Kingdom. Factors such as unemployment, interest rates and inflation could significantly affect the retail market. Whilst a short term worsening in economic conditions in the United Kingdom should not significantly adversely impact profitability, a sustained downturn over a number of years would possibly lead to reduced profits.

 

Liquidity and financing

Liquidity and financing risks relate to the Healthpoint Group's ability to pay for goods and services required to trade on a day-to-day basis. As part of the Dayes Group BV, the Healthpoint Group is included in the Dayes Group BV’s consortium of banks, enabling it to have in place sufficient working capital facilities as required.

 

Credit risk

The Healthpoint Group trades B2B with recognised creditworthy third parties. It is the Healthpoint Group's policy that all customers who wish to trade on credit terms are subject to credit vetting procedures. In addition, receivable balances are monitored on an ongoing basis with the result that the Healthpoint Group's exposure to bad debts is mitigated. As part of the Dayes Group BV, credit insurance is in place for the majority of its customers and is definitely in place for all the major customers.

HEALTHPOINT LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
Foreign exchange risk

The Healthpoint Group trades mainly in GBP and has minimal exposure in other currencies. Some imported products are acquired in US$ and EUR and are subject to currency fluctuations. Wherever possible the Healthpoint Group hedges its trade and uses a third party to provide advice and the most appropriate currency deals. Once the Healthpoint Group migrates to the Dayes Group BV banking consortium the hedging policy will be retained within the Dayes Group BV.

 

Regulatory compliance risk

The Healthpoint Group is subject to regulatory compliance risk which can arise from a failure to comply fully with laws, regulations or codes applicable. As well as Health & Safety, licensing and fire regulations, part of our business sector is robustly governed by the Medicines and Healthcare Products Regulatory Agency. Non-compliance can lead to fines, enforced suspension from sale of certain products or public reprimand.

 

Failure of information systems

The Healthpoint Group's business is dependent on the efficient and uninterrupted operation of information technology and computer systems, which are vulnerable to damage or interruption from power loss, telecommunications failure, sabotage, vandalism or similar misconduct. Contingency and recovery plans are in place in order to mitigate the impact of such failures.

Future developments and performance

Looking to the future the Healthpoint Group is expected to at least maintain its recent financial performance, but enhanced cross selling opportunities and economies of scale within the Dayes Group BV are expected to improve the performance even further.

 

In December 2024 Healthpoint Ltd acquired The Miles Group. The Miles Group is a syndicated company of sales people, this acquisition is believed to strengthen the sales of the Healthpoint portfolio of products into pharmacies nationwide along with additional opportunities for 3PL services to be offered to their clients.

On behalf of the board

Mrs A Parkinson
Director
22 September 2025
HEALTHPOINT LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -

The directors present their annual report and financial statements for the year ended 31 December 2024.

Principal activities

The principal activity of the company and group continued to be that of the wholesale supply of health and beauty products.

Results and dividends

The results for the year are set out on page 8.

Ordinary dividends were paid amounting to £6,002,515. The directors do not recommend payment of a further dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mr M Ryan
(Resigned 30 April 2024)
Mrs A Parkinson
Mr W Poppelaars
Mr W Meijerink
Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

Medium-sized companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the medium-sized companies exemption.

On behalf of the board
Mrs A Parkinson
Director
22 September 2025
HEALTHPOINT LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

HEALTHPOINT LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF HEALTHPOINT LIMITED
- 5 -
Opinion

We have audited the financial statements of Healthpoint Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

HEALTHPOINT LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF HEALTHPOINT LIMITED
- 6 -

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

 

In the light of the knowledge and understanding of the group and parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent company or to cease operations, or have no realistic alternative but to do so.

Auditor responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud, is detailed below:

HEALTHPOINT LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF HEALTHPOINT LIMITED
- 7 -

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Virginia Cooper FCA
Senior Statutory Auditor
For and on behalf of MHA, Statutory Auditor
Preston, United Kingdom
22 September 2025
MHA is the trading name of MHA Audit Services LLP, a limited liability partnership in England and Wales (registered number OC455542)
HEALTHPOINT LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
2024
2023
Notes
£
£
Turnover
3
21,003,736
21,722,938
Cost of sales
(16,088,348)
(16,906,291)
Gross profit
4,915,388
4,816,647
Distribution costs
(1,177,992)
(1,197,880)
Administrative expenses
(1,560,286)
(1,547,486)
Operating profit
4
2,177,110
2,071,281
Interest receivable and similar income
7
520
2,457
Profit before taxation
2,177,630
2,073,738
Tax on profit
8
(568,793)
(500,498)
Profit for the financial year
1,608,837
1,573,240
Profit for the financial year is all attributable to the owner of the parent company.
Total comprehensive income for the year is all attributable to the owner of the parent company.
HEALTHPOINT LIMITED
GROUP BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 9 -
2024
2023
Notes
£
£
£
£
Fixed assets
Goodwill
10
509,078
-
0
Tangible assets
11
348,577
16,499
857,655
16,499
Current assets
Stocks
14
4,514,146
4,516,061
Debtors
15
2,646,355
4,581,711
Cash at bank and in hand
212,468
2,346,045
7,372,969
11,443,817
Creditors: amounts falling due within one year
16
(3,619,984)
(2,454,438)
Net current assets
3,752,985
8,989,379
Total assets less current liabilities
4,610,640
9,005,878
Provisions for liabilities
Deferred tax liability
18
2,211
3,771
(2,211)
(3,771)
Net assets
4,608,429
9,002,107
Capital and reserves
Called up share capital
20
5,556
5,556
Share premium account
48,899
48,899
Capital redemption reserve
5,556
5,556
Profit and loss reserves
4,548,418
8,942,096
Total equity
4,608,429
9,002,107

These financial statements have been prepared in accordance with the provisions relating to medium-sized groups.

The financial statements were approved by the board of directors and authorised for issue on 22 September 2025 and are signed on its behalf by:
22 September 2025
Mrs A Parkinson
Director
Company registration number 03163208 (England and Wales)
HEALTHPOINT LIMITED
COMPANY BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 10 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
11
11,456
16,499
Investments
12
1,400,910
-
0
1,412,366
16,499
Current assets
Stocks
14
4,514,146
4,516,061
Debtors
15
1,989,400
4,581,711
Cash at bank and in hand
2,772
2,346,045
6,506,318
11,443,817
Creditors: amounts falling due within one year
16
(3,308,044)
(2,454,438)
Net current assets
3,198,274
8,989,379
Total assets less current liabilities
4,610,640
9,005,878
Provisions for liabilities
Deferred tax liability
18
2,211
3,771
(2,211)
(3,771)
Net assets
4,608,429
9,002,107
Capital and reserves
Called up share capital
20
5,556
5,556
Share premium account
48,899
48,899
Capital redemption reserve
5,556
5,556
Profit and loss reserves
4,548,418
8,942,096
Total equity
4,608,429
9,002,107

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £1,608,837 (2023 - £1,573,240 profit).

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 22 September 2025 and are signed on its behalf by:
22 September 2025
Mrs A Parkinson
Director
Company registration number 03163208 (England and Wales)
HEALTHPOINT LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 11 -
Share capital
Share premium account
Capital redemption reserve
Profit and loss reserves
Total
Notes
£
£
£
£
£
Balance at 1 January 2023
5,556
48,899
5,556
7,368,856
7,428,867
Year ended 31 December 2023:
Profit and total comprehensive income
-
-
-
1,573,240
1,573,240
Balance at 31 December 2023
5,556
48,899
5,556
8,942,096
9,002,107
Year ended 31 December 2024:
Profit and total comprehensive income
-
-
-
1,608,837
1,608,837
Dividends
9
-
-
-
(6,002,515)
(6,002,515)
Balance at 31 December 2024
5,556
48,899
5,556
4,548,418
4,608,429
HEALTHPOINT LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 12 -
Share capital
Share premium account
Capital redemption reserve
Profit and loss reserves
Total
Notes
£
£
£
£
£
Balance at 1 January 2023
5,556
48,899
5,556
7,368,856
7,428,867
Year ended 31 December 2023:
Profit and total comprehensive income for the year
-
-
-
1,573,240
1,573,240
Balance at 31 December 2023
5,556
48,899
5,556
8,942,096
9,002,107
Year ended 31 December 2024:
Profit and total comprehensive income
-
-
-
1,608,837
1,608,837
Dividends
9
-
-
-
(6,002,515)
(6,002,515)
Balance at 31 December 2024
5,556
48,899
5,556
4,548,418
4,608,429
HEALTHPOINT LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 13 -
2024
2023
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
26
4,477,186
1,288,928
Income taxes paid
(607,772)
(521,727)
Net cash inflow from operating activities
3,869,414
767,201
Investing activities
Purchase of business
(916,214)
-
Purchase of tangible fixed assets
(5,109)
(13,876)
Interest received
520
2,457
Net cash used in investing activities
(920,803)
(11,419)
Financing activities
Dividends paid to equity shareholders
(6,002,515)
-
0
Net cash used in financing activities
(6,002,515)
-
Net (decrease)/increase in cash and cash equivalents
(3,053,904)
755,782
Cash and cash equivalents at beginning of year
2,346,045
1,590,263
Cash and cash equivalents at end of year
(707,859)
2,346,045
Relating to:
Cash at bank and in hand
212,468
2,346,045
Bank overdrafts included in creditors payable within one year
(920,327)
-
HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 14 -
1
Accounting policies
Company information

Healthpoint Limited (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is .

 

The group consists of Healthpoint Limited and all of its subsidiaries.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:

 

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 15 -
1.2
Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.

 

Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.

1.3
Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Healthpoint Limited together with all entities controlled by the parent company (its subsidiaries).

 

All financial statements are made up to 31 December 2024. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.

1.4
Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.5
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 16 -
1.6
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years,

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.7
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
15% / 25% / 33% on cost
Fixtures and fittings
33% on cost
Computers
50% on cost
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

1.8
Fixed asset investments

Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.

 

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.9
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

 

The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 17 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.10
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.11
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.12
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 18 -
Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.13
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.14
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 19 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.15
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.16
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.17
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
2
Judgements and key sources of estimation uncertainty
(Continued)
- 20 -
Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Stock valuation

Stock is stated as the lower of cost and net realisable value. The value of all stock as well as the provision for slow moving and obsolete stock can have a significant influence on the stock valuation in the financial statements. A comprehensive review of the stock holding is carried out regularly.

3
Turnover and other revenue
2024
2023
£
£
Turnover analysed by geographical market
United Kingdom
20,681,498
21,418,439
European Union
255,252
218,481
Rest of the World
66,986
86,018
21,003,736
21,722,938
2024
2023
£
£
Other revenue
Interest income
520
2,457
4
Operating profit
2024
2023
£
£
Operating profit for the year is stated after charging:
Fees payable to the group's auditor for the audit of the group's financial statements
13,400
11,600
Depreciation of owned tangible fixed assets
10,152
8,415
Amortisation of intangible assets
-
41,615
Operating lease charges
51,552
51,390
HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 21 -
5
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2024
2023
2024
2023
Number
Number
Number
Number
Directors
2
2
2
2
Accounts & stock control
7
7
7
7
Product development
2
2
2
2
Graphical design
2
1
2
1
Quality control
2
2
2
2
Sales
5
5
5
5
Total
20
19
20
19

Their aggregate remuneration comprised:

Group
Company
2024
2023
2024
2023
£
£
£
£
Wages and salaries
1,016,493
986,760
1,016,493
986,760
Social security costs
109,807
111,906
109,807
111,906
Pension costs
55,612
53,719
55,612
53,719
1,181,912
1,152,385
1,181,912
1,152,385
6
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
145,743
208,958
Company pension contributions to defined contribution schemes
9,159
2,643
154,902
211,601

The number of directors for whom retirement benefits are accruing under defined contribution schemes amounted to 2 (2023 - 2).

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
6
Directors' remuneration
(Continued)
- 22 -
Remuneration disclosed above includes the following amounts paid to the highest paid director:
2024
2023
£
£
Remuneration for qualifying services
n/a
119,340
Company pension contributions to defined contribution schemes
n/a
1,321

As total directors' remuneration was less than £200,000 in the current year, no disclosure is provided for that year.

7
Interest receivable and similar income
2024
2023
£
£
Interest income
Interest on bank deposits
520
2,457
8
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
550,523
498,410
Adjustments in respect of prior periods
19,830
-
0
Total current tax
570,353
498,410
Deferred tax
Origination and reversal of timing differences
(1,560)
2,088
Total tax charge
568,793
500,498

Corporation tax is calculated at 25.00% (2023 - 23.52%) of the estimated assessable profit for the year. In the 3rd March 2021 Budget it was announced that the UK tax rate will increase to 25% from 1st April 2023, and this rate was substantively enacted on 24th May 2021. Deferred tax balances at the period end have been measured at 25% (2023 - 25%).

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
8
Taxation
(Continued)
- 23 -

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2024
2023
£
£
Profit before taxation
2,177,630
2,073,738
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 23.52%)
544,408
487,743
Tax effect of expenses that are not deductible in determining taxable profit
4,555
2,309
Change in unrecognised deferred tax assets
-
0
9,788
Adjustments in respect of prior years
19,830
784
Effect of change in corporation tax rate
-
(126)
Taxation charge
568,793
500,498
9
Dividends
2024
2023
Recognised as distributions to equity holders:
£
£
Final paid
6,002,515
-
10
Intangible fixed assets
Group
Goodwill
£
Cost
At 1 January 2024
130,000
Additions - business combinations
509,078
At 31 December 2024
639,078
Amortisation and impairment
At 1 January 2024 and 31 December 2024
130,000
Carrying amount
At 31 December 2024
509,078
At 31 December 2023
-
0
HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
10
Intangible fixed assets
(Continued)
- 24 -
Company
Goodwill
£
Cost
At 1 January 2024 and 31 December 2024
130,000
Amortisation and impairment
At 1 January 2024 and 31 December 2024
130,000
Carrying amount
At 31 December 2024
-
0
At 31 December 2023
-
0
11
Tangible fixed assets
Group
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 January 2024
106,532
17,253
-
0
-
0
123,785
Additions
5,109
-
0
-
0
-
0
5,109
Business combinations
-
0
3,094
5,122
328,905
337,121
At 31 December 2024
111,641
20,347
5,122
328,905
466,015
Depreciation and impairment
At 1 January 2024
94,372
12,914
-
0
-
0
107,286
Depreciation charged in the year
8,129
2,023
-
0
-
0
10,152
At 31 December 2024
102,501
14,937
-
0
-
0
117,438
Carrying amount
At 31 December 2024
9,140
5,410
5,122
328,905
348,577
At 31 December 2023
12,160
4,339
-
0
-
0
16,499
HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
11
Tangible fixed assets
(Continued)
- 25 -
Company
Plant and equipment
Fixtures and fittings
Total
£
£
£
Cost
At 1 January 2024
106,532
17,253
123,785
Additions
5,109
-
0
5,109
At 31 December 2024
111,641
17,253
128,894
Depreciation and impairment
At 1 January 2024
94,372
12,914
107,286
Depreciation charged in the year
8,129
2,023
10,152
At 31 December 2024
102,501
14,937
117,438
Carrying amount
At 31 December 2024
9,140
2,316
11,456
At 31 December 2023
12,160
4,339
16,499
12
Fixed asset investments
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Investments in subsidiaries
13
-
0
-
0
1,400,910
-
0
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 January 2024
-
Additions
1,400,910
At 31 December 2024
1,400,910
Carrying amount
At 31 December 2024
1,400,910
At 31 December 2023
-
13
Subsidiaries

Details of the company's subsidiaries at 31 December 2024 are as follows:

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
13
Subsidiaries
(Continued)
- 26 -
Name of undertaking
Address
Class of
% Held
shares held
Direct
Indirect
Miles (Sales Brokers) Limited
1
Ordinary
100.00
-
The Miles Group Limited
1
Ordinary
0
100.00

Registered office addresses (all UK unless otherwise indicated):

1
The Coach House, 21 Belmont Street, Huddersfield, West Yorkshire, HD1 5BZ

Miles (Sales Brokers) Limited (company registration number 03671627) and The Miles Group Limited (company registration number 01324083) have taken the exemption in Section 479A of the Companies Act 2006 ("the Act") from the requirements in the Act for their individual accounts to be audited. The guarantee given by the company under Section 479A of the Act is disclosed in note 22.

14
Stocks
Group
Company
2024
2023
2024
2023
£
£
£
£
Finished goods and goods for resale
4,514,146
4,516,061
4,514,146
4,516,061
15
Debtors
Group
Company
2024
2023
2024
2023
Amounts falling due within one year:
£
£
£
£
Trade debtors
1,913,635
2,333,914
1,465,943
2,333,914
Corporation tax recoverable
12,665
-
0
12,665
-
0
Amounts owed by group undertakings
-
1,002,515
-
1,002,515
Other debtors
446,418
1,173,600
446,318
1,173,600
Prepayments and accrued income
273,637
71,682
64,474
71,682
2,646,355
4,581,711
1,989,400
4,581,711
HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 27 -
16
Creditors: amounts falling due within one year
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Bank loans and overdrafts
17
920,327
-
0
920,327
-
0
Trade creditors
1,210,185
1,264,418
1,189,695
1,264,418
Amounts owed to group undertakings
-
0
1
-
0
1
Corporation tax payable
74,321
24,754
-
0
24,754
Other taxation and social security
363,301
442,671
237,758
442,671
Other creditors
280,878
-
0
275,000
-
0
Accruals and deferred income
770,972
722,594
685,264
722,594
3,619,984
2,454,438
3,308,044
2,454,438
17
Loans and overdrafts
Group
Company
2024
2023
2024
2023
£
£
£
£
Invoice discounting facility
920,327
-
0
920,327
-
0
Payable within one year
920,327
-
0
920,327
-
0

The invoice discounting facility is secured over the book debts of the company.

18
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

Liabilities
Liabilities
2024
2023
Group
£
£
Accelerated capital allowances
2,864
4,125
Retirement benefit obligations
(653)
(354)
2,211
3,771
HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
18
Deferred taxation
(Continued)
- 28 -
Liabilities
Liabilities
2024
2023
Company
£
£
Accelerated capital allowances
2,864
4,125
Retirement benefit obligations
(653)
(354)
2,211
3,771
Group
Company
2024
2024
Movements in the year:
£
£
Liability at 1 January 2024
3,771
3,771
Credit to profit or loss
(1,560)
(1,560)
Liability at 31 December 2024
2,211
2,211

It is not possible to quantify the amounts expected to reverse over the upcoming twelve months owing to uncertainties over the capital expenditure of the company.

19
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
55,612
53,719

A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.

20
Share capital
Group and company
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
5,556
5,556
5,556
5,556
HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 29 -
21
Acquisition of a business

On 3 December 2024 the group acquired 100 percent of the issued capital of Miles (Sales Brokers) Limited.

Book Value
Adjustments
Fair Value
Net assets acquired
£
£
£
Property, plant and equipment
337,121
-
337,121
Trade and other receivables
656,954
-
656,954
Cash and cash equivalents
209,696
-
209,696
Trade and other payables
(237,618)
-
(237,618)
Tax liabilities
(74,321)
-
(74,321)
Total identifiable net assets
891,832
-
891,832
Goodwill
509,078
Total consideration
1,400,910
The consideration was satisfied by:
£
Cash
1,125,910
Deferred consideration
275,000
1,400,910
Contribution by the acquired business for the reporting period included in the group statement of comprehensive income since acquisition:
£
Turnover
-
Profit after tax
-
22
Financial commitments, guarantees and contingent liabilities

Parent company guarantee

In order for the company's subsidiaries, Miles (Sales Brokers) Limited and The Miles Group Limited, to take the audit exemption in Section 479A of the Companies Act 2006, the company has guaranteed all outstanding liabilities of these subsidiaries at 31 December 2024 until those liabilities are satisfied in full.

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 30 -
23
Operating lease commitments
Lessee

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Group
Company
2024
2023
2024
2023
£
£
£
£
Within one year
42,996
45,983
42,996
45,983
Between two and five years
10,500
53,496
10,500
53,496
53,496
99,479
53,496
99,479
24
Related party transactions

During the year, the group which Healthpoint Limited was previously part of, headed by Healthpoint 2016 Limited, was simplified. Healthpoint 2014 Limited and Healthpoint 2016 Limited were dissolved, which made up the group balances as at 31 December 2023.

 

Other information

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard Applicable in the UK and Ireland', not to disclose related party transactions with wholly owed subsidiaries within the group.

25
Controlling party

The company is a wholly owned subsidiary of Dayes Group BV, a company registered in The Netherlands. The ultimate parent company is Nexus Newco BV, which is also registered in The Netherlands.

 

The largest group in which this company's results are consolidated is that headed by Nexus Newco BV, and the smallest group in which this company's results are consolidated is that headed by Dayes Group BV.

HEALTHPOINT LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 31 -
26
Cash generated from group operations
2024
2023
£
£
Profit for the year after tax
1,608,837
1,573,240
Adjustments for:
Taxation charged
568,793
500,498
Investment income
(520)
(2,457)
Amortisation and impairment of intangible assets
-
41,615
Depreciation and impairment of tangible fixed assets
10,152
8,415
Movements in working capital:
Decrease/(increase) in stocks
1,915
(376,337)
Decrease/(increase) in debtors
2,604,975
(144,320)
Decrease in creditors
(316,966)
(311,726)
Cash generated from operations
4,477,186
1,288,928
27
Analysis of changes in net funds/(debt) - group
1 January 2024
Cash flows
31 December 2024
£
£
£
Cash at bank and in hand
2,346,045
(2,133,577)
212,468
Bank overdrafts
-
0
(920,327)
(920,327)
2,346,045
(3,053,904)
(707,859)
2024-12-312024-01-01falsefalseCCH SoftwareCCH Accounts Production 2025.200Mr M RyanMrs A ParkinsonMr W PoppelaarsMr W Meijerinkfalse03163208bus:Consolidated2024-01-012024-12-31031632082024-01-012024-12-3103163208bus:Director22024-01-012024-12-3103163208bus:Director32024-01-012024-12-3103163208bus:Director42024-01-012024-12-3103163208bus:Director12024-01-012024-12-3103163208bus:RegisteredOffice2024-01-012024-12-31031632082024-12-3103163208bus:Consolidated2024-12-3103163208bus:Consolidated2023-01-012023-12-31031632082023-01-012023-12-3103163208core:Goodwillbus:Consolidated2024-12-3103163208core:Goodwillbus:Consolidated2023-12-3103163208core:Goodwill2024-12-3103163208core:Goodwill2023-12-3103163208bus:Consolidated2023-12-31031632082023-12-3103163208core:PlantMachinerybus:Consolidated2024-12-3103163208core:FurnitureFittingsbus:Consolidated2024-12-3103163208core:ComputerEquipmentbus:Consolidated2024-12-3103163208core:MotorVehiclesbus:Consolidated2024-12-3103163208core:PlantMachinerybus:Consolidated2023-12-3103163208core:FurnitureFittingsbus:Consolidated2023-12-3103163208core:ComputerEquipmentbus:Consolidated2023-12-3103163208core:MotorVehiclesbus:Consolidated2023-12-3103163208core:PlantMachinery2024-12-3103163208core:FurnitureFittings2024-12-3103163208core:PlantMachinery2023-12-3103163208core:FurnitureFittings2023-12-3103163208core:ShareCapitalbus:Consolidated2024-12-3103163208core:ShareCapitalbus:Consolidated2023-12-3103163208core:SharePremiumbus:Consolidated2024-12-3103163208core:SharePremiumbus:Consolidated2023-12-3103163208core:CapitalRedemptionReservebus:Consolidated2024-12-3103163208core:CapitalRedemptionReservebus:Consolidated2023-12-3103163208core:RetainedEarningsAccumulatedLossesbus:Consolidated2023-12-3103163208core:ShareCapital2024-12-3103163208core:ShareCapital2023-12-3103163208core:SharePremium2024-12-3103163208core:SharePremium2023-12-3103163208core:CapitalRedemptionReserve2024-12-3103163208core:CapitalRedemptionReserve2023-12-3103163208core:RetainedEarningsAccumulatedLosses2024-12-3103163208core:RetainedEarningsAccumulatedLosses2023-12-3103163208core:ShareCapitalbus:Consolidated2022-12-3103163208core:SharePremiumbus:Consolidated2022-12-3103163208core:CapitalRedemptionReservebus:Consolidated2022-12-31031632082022-12-3103163208core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-12-3103163208core:ShareCapital2022-12-3103163208core:SharePremium2022-12-3103163208core:CapitalRedemptionReserve2022-12-3103163208core:RetainedEarningsAccumulatedLosses2022-12-3103163208bus:Consolidated2022-12-3103163208core:Goodwill2024-01-012024-12-3103163208core:PlantMachinery2024-01-012024-12-3103163208core:FurnitureFittings2024-01-012024-12-3103163208core:ComputerEquipment2024-01-012024-12-3103163208core:MotorVehicles2024-01-012024-12-3103163208core:UKTaxbus:Consolidated2024-01-012024-12-3103163208core:UKTaxbus:Consolidated2023-01-012023-12-3103163208core:Goodwillbus:Consolidated2023-12-3103163208core:Goodwill2023-12-3103163208core:Goodwillbus:Consolidated2024-01-012024-12-3103163208core:PlantMachinerybus:Consolidated2023-12-3103163208core:FurnitureFittingsbus:Consolidated2023-12-3103163208core:ComputerEquipmentbus:Consolidated2023-12-3103163208core:MotorVehiclesbus:Consolidated2023-12-3103163208bus:Consolidated2023-12-3103163208core:PlantMachinery2023-12-3103163208core:FurnitureFittings2023-12-31031632082023-12-3103163208core:PlantMachinerybus:Consolidated2024-01-012024-12-3103163208core:FurnitureFittingsbus:Consolidated2024-01-012024-12-3103163208core:ComputerEquipmentbus:Consolidated2024-01-012024-12-3103163208core:MotorVehiclesbus:Consolidated2024-01-012024-12-3103163208core:Subsidiary12024-01-012024-12-3103163208core:Subsidiary22024-01-012024-12-3103163208core:Subsidiary112024-01-012024-12-3103163208core:Subsidiary222024-01-012024-12-3103163208core:CurrentFinancialInstruments2024-12-3103163208core:CurrentFinancialInstruments2023-12-3103163208core:CurrentFinancialInstrumentsbus:Consolidated2024-12-3103163208core:CurrentFinancialInstrumentsbus:Consolidated2023-12-3103163208core:WithinOneYearbus:Consolidated2024-12-3103163208core:WithinOneYearbus:Consolidated2023-12-3103163208core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3103163208core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3103163208core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-12-3103163208core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2023-12-3103163208bus:PrivateLimitedCompanyLtd2024-01-012024-12-3103163208bus:FRS1022024-01-012024-12-3103163208bus:Audited2024-01-012024-12-3103163208bus:ConsolidatedGroupCompanyAccounts2024-01-012024-12-3103163208bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP